Here's Why Momentum in Corcept (CORT) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Truist Securities raised the price target for Corcept Therapeutics Incorporated CORT and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it “is impressive and difficult to ignore.”
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corcept Shares Rise More Than 45% in Six Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
Corcept (CORT) Upgraded to Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade
The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can Corcept (CORT) Run Higher on Rising Earnings Estimates?
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline
Corcept Therapeutics' strong Q2 earnings exceed expectations, with revenue climbing 39% YoY and EPS beating analyst estimates. The District Court ruled in favor of Teva, enabling the launch of a generic Korlym, which threatens Corcept's revenue. Corcept faces a lawsuit accusing it of antitrust behavior and alleged illicit bribes.
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.
